261 related articles for article (PubMed ID: 28054548)
1. Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma.
Dai J; Wu S; Kong Y; Chi Z; Si L; Sheng X; Cui C; Fang J; Zhang J; Guo J
Sci Rep; 2017 Jan; 7():39597. PubMed ID: 28054548
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis initiation and angiogenesis inhibition: melanoma targets for nanosecond pulsed electric fields.
Chen X; Kolb JF; Swanson RJ; Schoenbach KH; Beebe SJ
Pigment Cell Melanoma Res; 2010 Aug; 23(4):554-63. PubMed ID: 20370854
[TBL] [Abstract][Full Text] [Related]
3. Targeted gold nanorods combined with low-intensity nsPEFs enhance antimelanoma efficacy in vitro.
Mi Y; Liu Q; Li P; Xu J; Yang Q; Tang J
Nanotechnology; 2020 Aug; 31(35):355102. PubMed ID: 32396891
[TBL] [Abstract][Full Text] [Related]
4. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.
Amirouchene-Angelozzi N; Frisch-Dit-Leitz E; Carita G; Dahmani A; Raymondie C; Liot G; Gentien D; Némati F; Decaudin D; Roman-Roman S; Schoumacher M
Oncotarget; 2016 Apr; 7(17):23633-46. PubMed ID: 26988753
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of long- and short-pulsed electric fields for treating melanoma in an in vivo mouse model.
Chen X; Chen X; Schoenbach KH; Zheng S; Swanson RJ
In Vivo; 2011; 25(1):23-7. PubMed ID: 21282730
[TBL] [Abstract][Full Text] [Related]
6. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
8. Histopathology of normal skin and melanomas after nanosecond pulsed electric field treatment.
Chen X; James Swanson R; Kolb JF; Nuccitelli R; Schoenbach KH
Melanoma Res; 2009 Dec; 19(6):361-71. PubMed ID: 19730404
[TBL] [Abstract][Full Text] [Related]
9. [The anti-tumor efficacy of nanosecond pulsed electric fields on the mouse with melanoma xenograft in vivo].
Peng Q; Dong S; Guo F; Yao C; Tang J
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Dec; 30(6):1302-8. PubMed ID: 24645616
[TBL] [Abstract][Full Text] [Related]
10. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
11. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
13. Nanosecond pulsed electric fields as a novel drug free therapy for breast cancer: an in vivo study.
Wu S; Wang Y; Guo J; Chen Q; Zhang J; Fang J
Cancer Lett; 2014 Feb; 343(2):268-74. PubMed ID: 24099912
[TBL] [Abstract][Full Text] [Related]
14. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of nanosecond electric fields in vitro and in vivo on hepatocellular carcinoma indicate macrophage infiltration contribute to tumor ablation in vivo.
Chen X; Yin S; Hu C; Chen X; Jiang K; Ye S; Feng X; Fan S; Xie H; Zhou L; Zheng S
PLoS One; 2014; 9(1):e86421. PubMed ID: 24475118
[TBL] [Abstract][Full Text] [Related]
16. Intense nanosecond pulsed electric fields promote cancer cell apoptosis through centrosome-dependent pathway involving reduced level of PLK1.
Zou H; Gan XL; Linghu LJ; Chen C; Hu LN; Zhang Y
Eur Rev Med Pharmacol Sci; 2013 Jan; 17(2):152-60. PubMed ID: 23377802
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S
Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207
[TBL] [Abstract][Full Text] [Related]
19. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.
Koldehoff M; Beelen DW; Elmaagacli AH
Cancer Gene Ther; 2014 Jul; 21(7):275-82. PubMed ID: 24903015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
